Latest Articles
King Saud University Study Identifies Proteomic Differences in Obesity-Related Endometrial Cancer - وكالة الأنباء السعودية
King Saud University Study Identifies Proteomic Differences in Obesity-Related Endometrial Cancer وكالة الأنباء السعودية
Published: April 14, 2026, 9:39 a.m.
Pathogenesis of Adenomyosis: An Integrated Review of Cellular Origins, Molecular Mechanisms, and Intersecting Diseases.
Adenomyosis is a prevalent disorder of the archimetra, historically conflated with endometriosis but possessing a unique pathobiological trajectory. This review synthesises current molecular evidence to propose a unified mechanistic framework …
Published: April 14, 2026, midnight
Monthly bleeding nasal endometriosis: a case report.
Endometriosis is a chronic gynecological disease defined as the presence of functional endometrial glands and stroma outside of the uterus. Depending on the area identified, endometriosis can be pelvic and …
Published: April 14, 2026, midnight
BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial - BioSpace
BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial BioSpace
Published: April 13, 2026, 5:57 p.m.
Near-Perfect Disease Control for Bispecific in Advanced Endometrial Cancer - MedPage Today
Near-Perfect Disease Control for Bispecific in Advanced Endometrial Cancer MedPage Today
Published: April 13, 2026, 3:43 p.m.
BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer - TipRanks
BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer TipRanks
Published: April 13, 2026, 12:29 p.m.
Biontech prepares FDA application after strong phase II results in endometrial cancer - medwatch.com
Biontech prepares FDA application after strong phase II results in endometrial cancer medwatch.com
Published: April 13, 2026, 12:14 p.m.
Endometrial cancer trial: BioNTech (Nasdaq: BNTX) ADC hits Phase 2 goal - Stock Titan
Endometrial cancer trial: BioNTech (Nasdaq: BNTX) ADC hits Phase 2 goal Stock Titan
Published: April 13, 2026, 11:55 a.m.
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data - Sahm
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data Sahm
Published: April 13, 2026, 10:35 a.m.
GSK (NYSE: GSK) reports Mo-Rez data in ovarian, endometrial cancer - Stock Titan
GSK (NYSE: GSK) reports Mo-Rez data in ovarian, endometrial cancer Stock Titan
Published: April 13, 2026, 10:23 a.m.
Link copied to clipboard!